Leukotriene Antagonists in Atopic Diseases and Acne;Leukotrienantagonisten bei Atopischen Erkrankungen und Akne

Aktuelle Dermatologie

Volumn 29, Issue 10, 2003, Pages 419-425

  Zouboulis, Ch C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; BECLOMETASONE; GLUCOCORTICOID; LEUKOTRIENE; LEUKOTRIENE B4; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PEPTIDOLEUKOTRIENE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PLACEBO; ZILEUTON;

ACNE; ALLERGIC RHINITIS; ARACHIDONIC ACID METABOLISM; ARTICLE; ASTHMA; ATOPIC DERMATITIS; CATALYSIS; ENDOTHELIUM CELL; HUMAN; INFLAMMATION; LIPOGENESIS; LOW DRUG DOSE; PURKINJE CELL; RHINOCONJUNCTIVITIS; SKIN DISEASE; SMOOTH MUSCLE;

EID: 0242653598     PISSN: 03402541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-43493     Document Type: Article

References (63)

1. Funk CD. Prostaglandins and leukotrienes: Advances in eicosanoid biology. Science 2001; 294: 1871-1875
2. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W. The PPAR α-leucotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43
3. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schneider C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR, Dubois RN. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res 2001; 61: 497-503
4. Garcia-Marcos L, Schuster A. Antileukotrienes in asthma: present situation. Expert Opin Pharmacother 2001; 2: 441-466
5. Zhu YI, Stiller MJ. Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol 2000; 13: 235-245
6. Wedi B, Kapp A. Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs 2001; 15: 729-743
7. Smith KJ, Skelton H. Arachidonic acid-derived bioactive lipids: their role and the role for their inhibitors in dermatology. J Cutan Med Surg 2002; 6: 241-256
8. Zemtsov A, Bucchino S, McDowell MR. Potential use of leukotriene inhibitors in treatment of psoriasis. Dermatology 2003; 206: 179-180
9. Zouboulis ChC, Nestoris S, Adler YD, Picardo M, Camera E, Orth M, Orfanos CE, Cunliffe WJ. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003; 139: 668-670
10. Garcia-Marcos L, Schuster A, Perez-Yarza E. Benefit-risk assessment of antileukotrienes in the management of asthma, Drug Saf 2003; 26: 483-518
11. Ducharme FM. Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Br Med J 2003; 326: 621-625
12. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. Br Med J 2002; 324: 1545-1551
13. Nathan RA. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. Ann Allergy Asthma Immunol 2003; 90: 182-190
14. Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, Malice MP, Reiss TF. Montelukast Spring Rhinitis Study Group. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002; 32: 1020-1028
15. Piatti G, Ceriotti L, Cavallaro G, Ambrosetti U, Mantovani M, Pistone A, Centanni S. Effects of zafirlukast on bronchial asthma and allergic rhinitis. Pharmacol Res 2003; 47: 541-547
16. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4-receptor antagonist, JCl 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995; 151: 1734-1739
17. van Adelsberg J, Philip G, LaForce CF, Weinstein SF, Menten J, Malice MP, Reiss TF. Montelukast Spring Rhinitis Investigator Group. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90: 214-222
18. Pullerits T, Praks L, Ristioja V, Lotvall J. Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109: 949-955
19. Ratner PH, Howland WC, 3rd, Arastu R, Philpot EE, Klein KC, Baidoo CA, Faris MA, Rickard KA. Fluticasone propionate aqueous nasal spray provided significantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003; 90: 536-542
20. Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Montelukast Fall Rhinitis Investigator Group. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002; 88: 592-600
21. Koro O, Furutani K, Hide M, Yamada S, Yamamoto S. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type 1 allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999; 103: 663-670
22. Talbot SF, Atkins PC, Goetzel EJ, Zweimann B. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Invest 1985; 76: 650-656
23. James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils. J Allergy Clin Immunol 1993; 91: 1155-1162
24. 4 generation by blood leukocytes after ex vivo stimulation by Ca-ionophore and opsonized zymosan in children with atopic dermatitis. Pediatr Allergy Immunol 1994; 5: 95-99
25. 4 excretion in normal and asthmatic subjects. Am Rev Respir Dis 1993; 148: 1244-1251
26. 4 levels in patients with atopic dermatitis. Br J Dermatol 1997; 136: 790-791
27. Hishinuma T, Suzuki N, Aiba S, Tagami H, Mizugaki M. Increased urinary leukotriene E4 excretion in patients with atopic dermatitis. Br J Dermatol 2001; 144: 19-23
28. Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998; 134: 785-786
29. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999; 83: 548-552
30. Kägi MK. Leukotriene receptor antagonists - a novel therapeutic approach in atopic dermatitis? Dermatology 2001; 203: 280-283
31. Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults. Eur J Dermatol 2001; 11: 209-213
32. Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol. 2001; 44: 89-93
33. Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol 2001; 12: 154-158
34. Nettis E, Pannofino A, Fanelli M, Ferrannini A, Tursi A. Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta Derm Venereol 2002; 82: 297-298
35. Burkhart CG, Cantrill J, Butcher CL, Lehmann PF. Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody. Int J Dermatol 1999; 38: 200-203
36. Zouboulis ChC. Is acne vulgaris a genuine inflammatory disease? Dermatology 2001; 203: 277-279
37. Eady EA, Cove JH. Is acne an infection of blocked pilosebaceous follicles? Implications for antimicrobial treatment. Am J Clin Dermatol 2000; 1: 201-209
38. Ingham E, Eady EA, Goodwin CE, Cove JH, Cunliffe WJ. Pro-inflammatory levels of interleukin-1 alpha-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol 1992; 98: 895-901
39. Antilla HS, Reitamo S, Saurat J-H. Interleukin 1 immunoreactivity in sebaceous glands. Br J Dermatol 1992; 127: 585-588
40. Boehm KD, Yun JK, Strohl KP, Elmets CA. Messenger RNAs for the multifunctional cytokines interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor-alpha are present in adnexal tissues and in dermis of normal human skin. Exp Dermatol 1995; 4: 335-341
41. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106: 176-182
42. Holland KT, Cunliffe WJ, Roberts CD. Acne vulgaris: an investigation into the number of anaerobic diphtheroids and members of the Micrococcaceae in nornal and acne skin. Brit J Dermatol 1977; 96: 623-626
43. Ingham E, Walters CE, Eady EA, Cove JH, Kearney JN, Cunliffe WJ. Inflammation in acne vulgaris: failure of skin micro-organisms to modulate keratinocyte interleukin 1 alpha production in vitro. Dermatology 1998; 196: 86-88
44. Valacchi G, Rimbach G, Saliou C, Weber SU, Packer L. Effect of benzoyl peroxide on antioxidant status, NF-kB activity and interleukin-1° gene expression in human keratinocytes. Toxicology 2001; 165: 225-234
45. Akamatsu H, Tomita T, Horio T. Effects of Roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology 2002; 204: 277-280
46. Delerive P, Fruchart J-C, Staels B. Eurosterone Meeting - Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 2001; 169: 453-459
47. Thuillier P, Brash AR, Kehrer JP, Stimmel JB, Leesnitzer LM, Yang P, Newman RA, Fischer SM. Inhibition of peroxisome-proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors. Biochem J 2001; 366: 901-910
48. Wróbel A, Seltmann H, Fimmel S, Müller-Decker K, Tsukada M, Bogdanoff B, Mandt N, Blume-Peytavi U, Orfanos CE, Zouboulis ChC. Differentiation and apoptosis in human immortalized sebocytes. J Invest Dermatol 2003; 120: 175-181
49. Alestas T, Chen W, Zouboulis ChC. Arachidonic acid activates the leukotriene inflammatory signaling pathway in SZ95 sebocytes in vitro. Arch Dermatol Res 2003; 295: 490
50. Shappell SB, Keeney DS, Zhang J, Page R, Olson SJ, Brash AR. 15-Lipoxygenase-2 expression in benign and neoplastic sebaceous glands and other cutaneous adnexa. J Invest Dermatol 2001; 117: 36-43
51. Chen W, Yang C-C, Sheu H-M, Seltmann H, Zouboulis ChC. Expression of PPAR and c/EBP transcription factors in cultured human sebocytes. J Invest Dermatol 2003; in press (online publication: 30. 6. 2003)
52. Kehrer JP, Biswal SS, La E, Datta K, Fischer SM, Vanden Heuvel JP. Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. Biochem J 2001; 356: 899-906
53. Smith KJ, Dipreta E, Skelton H. Peroxisomes in dermatology. Part II. J Cutan Med Surg 2001; 5: 315-322
54. Rosenfield RL, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology 1998; 196: 43-46
55. Wozel G, Chang A, Zultak M, Czarnetzki BM, Happle R, Barth J, van de Kerkhof PC. The effect of topical retinoids on the leukotriene-B4-induced migration of polymorphonuclear leukocytes into human skin. Arch Dermatol Res 1991; 283: 158-161
56. Allen BS, Smith JG. Various parameters for grading acne. Arch Dermatol 1982; 118: 23-25
57. Hindson C, Lawlor F, Wacks H. Benoxaprofen for nodular acne. Lancet 1982; 1 (8286): 1415
58. Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. J Am Acad Dermatol 1984; 11: 1076-1081
59. Strauss JS, Pochi PE, Whitman EN. Suppression of sebaceous gland activity with eicosa-5:8: 11:14-tetraynoic acid. J Invest Dermatol 1967; 48: 492-493
60. Burton JL, Shuster S. Topical tetraynoic acid and sebum secretion. Br J Dermatol 1970; 82: 626-627
61. Haroon TS, Hall J, Lyell A, Alexander jO'D. Topical tetraynoic acid. Br J Dermatol 1970; 83: 418-419
62. Holgate ST, Sampson AP. Antileukotriene therapy. Future directions. Am J Respir Crit Care Med 2000; 161: 147-153
63. Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108: 175-183